About Coagulant Therapeutics, Inc.

The startup develops therapeutic drugs utilizing a proprietary recombinant factor VIIa (rFVIIa) molecule, CT-001, for the prevention and treatment of acute bleeding and coagulation disorders. Their focus on biologics enables targeted therapies that enhance treatment outcomes for traumatic injuries, ultimately aiming to improve survival rates among young patients.

```xml <problem> Acute bleeding, encompassing conditions like postpartum hemorrhage, intracranial hemorrhage, and traumatic injuries, remains a leading cause of death, with a significant percentage of hemorrhage-related deaths potentially preventable. Currently, there are limited or no approved drugs specifically designed to treat acute bleeding episodes. </problem> <solution> Coagulant Therapeutics is developing a portfolio of hemostatic agents, including CT-001, a novel recombinant Factor VIIa (rFVIIa) molecule, and a library of nanobodies targeting Activated Protein C (APC), to address the unmet medical need for acute bleeding treatments. CT-001 is engineered for enhanced activity and safety, designed to rapidly clear from the system, reducing the risk of thrombo-embolic events. The APC-targeting nanobodies, including lead candidates CT-003 and CT-005, selectively modulate APC functions to ameliorate trauma-induced coagulopathy and other bleeding disorders. These biologics-based therapeutics aim to provide rapid hemostatic control and improve outcomes in various acute bleeding indications. </solution> <features> - CT-001: A novel rFVIIa variant engineered for faster clearance and superior efficacy in pre-clinical models. - APC Nanobody Library: A collection of llama-derived nanobodies targeting APC, enabling selective modulation of its coagulation, inflammation, and histone cleavage functions. - CT-003/CT-005: Lead nanobody candidates that shift PAR1 signaling towards anti-inflammation and cytoprotection, potentially ameliorating endotheliopathy. - Demonstrated superior potency and safety of CT-001 compared to rFVIIa in multiple murine acute bleeding models. - CT-001 corrects APTT of hypocoagulable plasma, indicating pro-hemostatic activity under coagulopathic conditions. - Nanobodies exhibit high stability, making them suitable for liquid formulation in diverse settings. </features> <target_audience> The primary target audience includes medical professionals treating patients experiencing acute bleeding events, such as those resulting from trauma, surgery, or obstetric complications, as well as clinical researchers focused on coagulation disorders and acute care. </target_audience> ```

What does Coagulant Therapeutics, Inc. do?

Where is Coagulant Therapeutics, Inc. located?

Coagulant Therapeutics, Inc. is based in Berkeley, United States.

When was Coagulant Therapeutics, Inc. founded?

Coagulant Therapeutics, Inc. was founded in 2017.

How much funding has Coagulant Therapeutics, Inc. raised?

Coagulant Therapeutics, Inc. has raised 38000000.

Location

Berkeley, United States

Founded

2017

Funding

38000000

Employees

4 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Coagulant Therapeutics, Inc.

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

coagulanttherapeutics.com 200+

Crunchbase

Founded 2017 – Berkeley, United States

Funding

Estimated Funding

$20M+

Team (<5)

No team information available.

Company Description

Problem

Acute bleeding, encompassing conditions like postpartum hemorrhage, intracranial hemorrhage, and traumatic injuries, remains a leading cause of death, with a significant percentage of hemorrhage-related deaths potentially preventable. Currently, there are limited or no approved drugs specifically designed to treat acute bleeding episodes.

Solution

Coagulant Therapeutics is developing a portfolio of hemostatic agents, including CT-001, a novel recombinant Factor VIIa (rFVIIa) molecule, and a library of nanobodies targeting Activated Protein C (APC), to address the unmet medical need for acute bleeding treatments. CT-001 is engineered for enhanced activity and safety, designed to rapidly clear from the system, reducing the risk of thrombo-embolic events. The APC-targeting nanobodies, including lead candidates CT-003 and CT-005, selectively modulate APC functions to ameliorate trauma-induced coagulopathy and other bleeding disorders. These biologics-based therapeutics aim to provide rapid hemostatic control and improve outcomes in various acute bleeding indications.

Features

CT-001: A novel rFVIIa variant engineered for faster clearance and superior efficacy in pre-clinical models.

APC Nanobody Library: A collection of llama-derived nanobodies targeting APC, enabling selective modulation of its coagulation, inflammation, and histone cleavage functions.

CT-003/CT-005: Lead nanobody candidates that shift PAR1 signaling towards anti-inflammation and cytoprotection, potentially ameliorating endotheliopathy.

Demonstrated superior potency and safety of CT-001 compared to rFVIIa in multiple murine acute bleeding models.

CT-001 corrects APTT of hypocoagulable plasma, indicating pro-hemostatic activity under coagulopathic conditions.

Nanobodies exhibit high stability, making them suitable for liquid formulation in diverse settings.

Target Audience

The primary target audience includes medical professionals treating patients experiencing acute bleeding events, such as those resulting from trauma, surgery, or obstetric complications, as well as clinical researchers focused on coagulation disorders and acute care.